slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 2,671-2,700
Pages 3,225
Rows per page 30
Component
2,671-2,700 of 96,741
165
Uses a 'The Conversation' article as a diagnostic framework to critique the subject company.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction3 hits
51
The slide uses visual evidence to argue for data fabrication in a clinical trial report.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
191
The slide uses direct quotes from investigators to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
197
Includes screenshots of FDA Orange Book data and the front page of US Patent 7,572,789.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
212
The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
238
The slide uses direct quotes from an ex-employee to undermine the credibility of the company's clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
242
The slide uses direct quotes from a Key Opinion Leader (KOL) to build a case against the drug's safety and market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
244
The slide uses direct quotes to build a case of corporate malfeasance regarding safety disclosures.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
249
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
252
The slide uses direct quotes from a KOL to undermine the company's marketing narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
264
The slide uses direct quotes and expert testimony to build a case against the credibility of a key opinion leader (Miller).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
288
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug Vykat, specifically highlighting the risk of electrolyte depletion when combined with diuretics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
314
The slide uses a Q&A format to highlight expert opinion against the subject drug (DCCR/Vykat).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
25
The slide uses a 'villain critique' approach to frame the company's business model as a 'government pay scam'.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Exposure of Contradictions3 hits
31
The slide uses direct quotes from an industry executive to build a bearish case against TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
49
Uses direct quotes from an ex-logistics manager to frame the company as a service provider rather than a medical device company.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
61
The slide uses direct quotes from KOLs to build a case against the company's pricing model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
67
The slide uses direct quotes from a transplant surgeon to support the claim of coercive business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
130
Includes direct quotes from a transplant hepatologist at Mass General Hospital to support the thesis of perverse incentives.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
163
The slide uses direct quotes to expose a misalignment between the stated value proposition (reduced hospitalization) and the actual usage (scheduling convenience).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
166
The slide uses direct quotes from UCSF hospital administrators to frame the argument that TransMedics usage is being curtailed due to cost and lack of clinical indication.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
180
The slide uses a specific study to challenge the safety/efficacy claims of machine perfusion vendors like TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
245
The slide uses a Q&A format to highlight alleged safety violations and hospital staff complaints.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
250
The slide uses strong, emotive language to frame the company's leadership as the primary antagonist.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
253
The slide uses highlighted text to emphasize key quotes from former executives regarding the CEO's professional conduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
266
The slide uses direct quotes to characterize the CEO as 'arrogant' and the company's behavior as 'extortion' and 'aggressive'.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
290
The slide uses a Q&A format to highlight the perceived lack of value proposition for the OCS Lung product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
291
The slide uses direct quotes from a surgeon to undermine the company's value proposition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
293
The slide uses expert testimonials to argue that the TransMedics device is 'fatally flawed' because it does not allow for functional assessment under load.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
294
The slide uses direct quotes from surgeons to validate the market share shift thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits